Evidences support the early use of SGLT2 inhibitors in T2DM patients with high cardiovascular or renal risk, and trials such as the EMPA-REG OUTCOME and Study of Heart and Kidney Protection With Empagliflozin (EMPA-KIDNEY) have shown that empagliflozin significantly reduces cardiovascular events and slows kidney disease progression, independent of glycemic control [30,35]. This evidence concerns the gene SLC5A2 and kidney disorder.